The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today recommended the two-dose Novavax COVID-19 vaccine as a COVID-19 vaccine primary series for emergency use in adults. If the CDC endorses ACIP’s recommendation, the protein-based vaccine would offer an option to individuals who may have an allergic reaction to or prefer not to receive an mRNA vaccine. The FDA last week authorized the vaccine for individuals age 18 and older. The departments of Health and Human Services and Defense this month secured 3.2 million doses of the vaccine to give states, federal pharmacy partners and federally qualified health centers. The vaccine can be stored at 2-8 degrees Celsius (about 36-46 degrees Fahrenheit), enabling the use of existing vaccine supply and cold chain channels.

Related News Articles

Headline
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public…
Headline
The United States July 7 reached its highest annual measles case tally in 33 years, hitting at least 1,277 confirmed cases across 38 states and the District of…
Headline
The Administration for Strategic Preparedness and Response June 25 announced it conducted an exercise transporting simulated patients with high-consequence…
Headline
Ochsner Health's Stephen Saenz, sepsis program manager, and Teresa Arrington, director of robust process improvement for quality and patient safety, reveal how…